Quest Diagnostics Incorporated: peers
Quest Diagnostics Incorporated beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Quest Diagnostics Incorporatedbase DGX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Labcorp Holdings Inc. LH · 🇺🇸 US Percentile in Healthcare Percentile in USA | DexCom, Inc. DXCM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Guardant Health, Inc. GH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Mettler-Toledo International Inc. MTD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Illumina, Inc. ILMN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Medpace Holdings, Inc. MEDP · 🇺🇸 US Percentile in Healthcare Percentile in USA | IDEXX Laboratories, Inc. IDXX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $27.8 BOct 30, 2026 · Market data5th of 8 | $26.3 BOct 22, 2026 · Market data6th of 8 | $29.9 BOct 22, 2026 · Market data4th of 8 | $24.1 BOct 28, 2026 · Market data7th of 8 | $32.5 BOct 21, 2026 · Market data3rd of 8 | $40.7 BOct 26, 2026 · Market data2nd of 8 | $19.0 BOct 30, 2026 · Market data8th of 8 | $41.5 BOct 6, 2026 · Market data1st of 8 | $28.9 B8 ranked |
| Revenue (Better neither way: ranked highest first) | $11.0 BFY2025 · SEC2nd of 8 | $14.0 BFY2025 · SEC1st of 8 | $4.7 BFY2025 · SEC3rd of 8 | $982 MFY2025 · SEC8th of 8 | $4.0 BFY2025 · SEC6th of 8 | $4.3 BFY2025 · SEC4th of 8 | $2.5 BFY2025 · SEC7th of 8 | $4.3 BFY2025 · SEC5th of 8 | $4.3 B8 ranked |
| Net income (Higher is better) | $992 MFY2025 · SEC2nd of 8 | $877 MFY2025 · SEC3rd of 8 | $836 MFY2025 · SEC6th of 8 | $-416 MFY2025 · SEC8th of 8 | $869 MFY2025 · SEC4th of 8 | $850 MFY2025 · SEC5th of 8 | $451 MFY2025 · SEC7th of 8 | $1.1 BFY2025 · SEC1st of 8 | $860 M8 ranked |
| Employees (Better neither way: ranked highest first) | 57,000December 31, 2025 · Profile2nd of 8 | 80,000As on 2022 · Profile1st of 8 | 11,100December 31, 2025 · Profile3rd of 8 | 2,506December 31, 2025 · Profile7th of 8 | 1,600December 31, 2025 · Profile8th of 8 | 10,200As on Jan-2023 · Profile5th of 8 | 6,200December 31, 2025 · Profile6th of 8 | 10,780As on 2022 · Profile4th of 8 | 10,4908 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | +11.8%FY2025 · SEC4th of 854th65th | +7.3%FY2025 · SEC6th of 843rd53rd | +15.6%FY2025 · SEC3rd of 860th72nd | +32.9%FY2025 · SEC1st of 879th87th | +4.0%FY2025 · SEC7th of 834th42nd | -0.7%FY2025 · SEC8th of 824th27th | +20.0%FY2025 · SEC2nd of 868th79th | +10.4%FY2025 · SEC5th of 851st63rd | +11.1%8 ranked |
| Revenue growth, 3 years a year (Higher is better) | +3.7%FY2025 · SEC6th of 838th48th | +5.5%FY2025 · SEC5th of 843rd55th | +17.0%FY2025 · SEC3rd of 868th82nd | +29.8%FY2025 · SEC1st of 881st92nd | +0.9%FY2025 · SEC7th of 829th36th | -1.8%FY2025 · SEC8th of 822nd26th | +20.1%FY2025 · SEC2nd of 872nd85th | +8.5%FY2025 · SEC4th of 850th65th | +7.0%8 ranked |
| Earnings per share growth (Higher is better) | +13.8%FY2025 · SEC5th of 655th56th | +18.3%FY2025 · SEC4th of 661st61st | +47.2%FY2025 · SEC1st of 675th80th | ———— | +3.9%FY2025 · SEC6th of 642nd43rd | ———— | +21.0%FY2025 · SEC3rd of 663rd64th | +22.6%FY2025 · SEC2nd of 665th65th | +19.7%6 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 33.2%FY2025 · SEC6th of 719th40th | 28.8%FY2025 · SEC7th of 715th33rd | 60.1%FY2025 · SEC4th of 753rd74th | 64.5%FY2025 · SEC2nd of 759th78th | 59.4%FY2025 · SEC5th of 752nd73rd | 66.1%FY2025 · SEC1st of 762nd79th | ———— | 61.8%FY2025 · SEC3rd of 755th76th | 60.1%7 ranked |
| Operating margin (Higher is better) | 14.1%FY2025 · SEC5th of 781st77th | 9.9%FY2025 · SEC6th of 773rd68th | 19.6%FY2025 · SEC3rd of 788th85th | -44.5%FY2025 · SEC7th of 733rd16th | ———— | 18.6%FY2025 · SEC4th of 787th84th | 21.1%FY2025 · SEC2nd of 789th87th | 31.6%FY2025 · SEC1st of 795th94th | 18.6%7 ranked |
| Net margin (Higher is better) | 9.0%FY2025 · SEC6th of 878th72nd | 6.3%FY2025 · SEC7th of 872nd65th | 17.9%FY2025 · SEC4th of 889th87th | -42.4%FY2025 · SEC8th of 832nd16th | 21.6%FY2025 · SEC2nd of 891st91st | 19.6%FY2025 · SEC3rd of 889th89th | 17.8%FY2025 · SEC5th of 888th87th | 24.6%FY2025 · SEC1st of 892nd92nd | 17.9%8 ranked |
| Free cash flow margin (Higher is better) | 12.3%FY2025 · SEC6th of 875th75th | 8.6%FY2025 · SEC7th of 869th66th | 23.1%FY2025 · SEC3rd of 892nd91st | -23.7%FY2025 · SEC8th of 836th16th | 21.1%FY2025 · SEC5th of 889th89th | 21.4%FY2025 · SEC4th of 890th89th | 26.9%FY2025 · SEC1st of 895th94th | 24.6%FY2025 · SEC2nd of 893rd93rd | 21.3%8 ranked |
| Return on equity (Higher is better) | 14.2%FY2025 · SEC5th of 686th76th | 10.5%FY2025 · SEC6th of 681st66th | 34.5%FY2025 · SEC3rd of 695th93rd | ———— | ———— | 33.4%FY2025 · SEC4th of 695th93rd | 70.2%FY2025 · SEC1st of 698th97th | 66.2%FY2025 · SEC2nd of 698th97th | 33.9%6 ranked |
| Return on invested capital (Higher is better) | 9.5%FY2025 · SEC2nd of 241st44th | ———— | ———— | ———— | ———— | ———— | ———— | 57.3%FY2025 · SEC1st of 298th97th | 33.4%2 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 24.6×price Oct 30, 2026 · Market data7th of 743rd63rd | 26.2×price Oct 22, 2026 · Market data6th of 745th66th | 30.2×price Oct 22, 2026 · Market data5th of 751st72nd | ———— | 34.8×price Oct 21, 2026 · Market data4th of 754th77th | 45.5×price Oct 26, 2026 · Market data1st of 769th85th | 36.6×price Oct 30, 2026 · Market data2nd of 758th79th | 35.1×price Oct 6, 2026 · Market data3rd of 755th78th | 34.8×7 ranked |
| Price to sales (Better neither way: ranked highest first) | 2.4×price Oct 30, 2026 · Market data7th of 838th52nd | 1.8×price Oct 22, 2026 · Market data8th of 831st45th | 5.9×price Oct 22, 2026 · Market data6th of 861st80th | 18.8×price Oct 28, 2026 · Market data1st of 882nd94th | 7.7×price Oct 21, 2026 · Market data4th of 867th86th | 9.0×price Oct 26, 2026 · Market data2nd of 872nd88th | 6.7×price Oct 30, 2026 · Market data5th of 864th83rd | 8.9×price Oct 6, 2026 · Market data3rd of 871st88th | 7.2×8 ranked |
| Price to book (Better neither way: ranked highest first) | 3.9×price Oct 30, 2026 · Market data5th of 659th70th | 3.0×price Oct 22, 2026 · Market data6th of 650th62nd | 10.9×price Oct 22, 2026 · Market data4th of 685th90th | ———— | ———— | 15.0×price Oct 26, 2026 · Market data3rd of 690th94th | 41.3×price Oct 30, 2026 · Market data1st of 697th98th | 25.9×price Oct 6, 2026 · Market data2nd of 694th97th | 12.9×6 ranked |
| Free cash flow yield (Higher is better) | 4.9%price Oct 30, 2026 · Market data1st of 887th66th | 4.6%price Oct 22, 2026 · Market data2nd of 885th64th | 3.6%price Oct 22, 2026 · Market data3rd of 881st57th | -1.0%price Oct 28, 2026 · Market data8th of 865th35th | 2.6%price Oct 21, 2026 · Market data5th of 878th50th | 2.3%price Oct 26, 2026 · Market data7th of 876th48th | 3.6%price Oct 30, 2026 · Market data3rd of 881st57th | 2.5%price Oct 6, 2026 · Market data6th of 877th50th | 3.1%8 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 0.8×FY2025 · SEC3rd of 369th60th | 0.6×FY2025 · SEC2nd of 359th49th | ———— | ———— | ———— | ———— | ———— | 0.3×FY2025 · SEC1st of 338th29th | 0.6×3 ranked |
| Net debt to EBITDA (Lower is better) | 2.5×FY2025 · SEC3rd of 361st56th | 2.2×FY2025 · SEC2nd of 354th52nd | ———— | ———— | ———— | ———— | ———— | 0.2×FY2025 · SEC1st of 330th21st | 2.2×3 ranked |
| Interest cover (Higher is better) | ———— | 6.2×FY2025 · SEC2nd of 387th77th | 63.8×FY2025 · SEC1st of 399th97th | -112.1×FY2025 · SEC3rd of 313th6th | ———— | ———— | ———— | ———— | 6.2×3 ranked |
| Piotroski F-score (Higher is better) | 8 of 9FY2025 · SEC1st of 5 | 8 of 9FY2025 · SEC1st of 5 | —— | 5 of 9FY2025 · SEC4th of 5 | 5 of 9FY2025 · SEC4th of 5 | —— | —— | 8 of 9FY2025 · SEC1st of 5 | 8.0 of 95 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 18 of 29FY2025 · Scorecard5th of 8 | 20 of 28FY2025 · Scorecard3rd of 8 | 18 of 24FY2025 · Scorecard1st of 8 | 7 of 22FY2025 · Scorecard8th of 8 | 11 of 19FY2025 · Scorecard6th of 8 | 11 of 23FY2025 · Scorecard7th of 8 | 16 of 23FY2025 · Scorecard4th of 8 | 19 of 26FY2025 · Scorecard2nd of 8 | 66% passed8 ranked |
| Valuation checks (Higher is better) | 2 of 6FY2025 · Scorecard2nd of 8 | 3 of 6FY2025 · Scorecard1st of 8 | 1 of 6FY2025 · Scorecard3rd of 8 | 0 of 5FY2025 · Scorecard7th of 8 | 1 of 6FY2025 · Scorecard3rd of 8 | 0 of 6FY2025 · Scorecard7th of 8 | 1 of 6FY2025 · Scorecard3rd of 8 | 1 of 6FY2025 · Scorecard3rd of 8 | 17% passed8 ranked |
| Growth checks (Higher is better) | 3 of 6FY2025 · Scorecard7th of 8 | 4 of 6FY2025 · Scorecard4th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard4th of 8 | 4 of 6FY2025 · Scorecard4th of 8 | 2 of 6FY2025 · Scorecard8th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 67% passed8 ranked |
| Profitability checks (Higher is better) | 3 of 6FY2025 · Scorecard7th of 8 | 3 of 5FY2025 · Scorecard6th of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 1 of 4FY2025 · Scorecard8th of 8 | 2 of 2FY2025 · Scorecard1st of 8 | 4 of 5FY2025 · Scorecard5th of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 90% passed8 ranked |
| Financial health checks (Higher is better) | 5 of 5FY2025 · Scorecard1st of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 4 of 4FY2025 · Scorecard1st of 8 | 2 of 4FY2025 · Scorecard8th of 8 | 2 of 2FY2025 · Scorecard1st of 8 | 3 of 3FY2025 · Scorecard1st of 8 | 2 of 3FY2025 · Scorecard7th of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 100% passed8 ranked |
| Shareholder returns checks (Higher is better) | 5 of 6FY2025 · Scorecard1st of 8 | 4 of 5FY2025 · Scorecard2nd of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 0 of 3FY2025 · Scorecard8th of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 1 of 3FY2025 · Scorecard7th of 8 | 67% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 93.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 95.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 98.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 98.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 100.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 106.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 82.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 93.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 96.6%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 1,1392026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 1,0802026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 1,0542026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 6732026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 8432026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 1,1112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 7592026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 1,2782026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 1,0678 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +2.9 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | +3.0 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | +8.2 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | -3.8 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +4.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +0.5 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +4.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | +3.9 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | +3.4 pp8 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | 1.3%FY2025 · SEC1st of 261st33rd | 0.9%FY2025 · SEC2nd of 248th24th | ———— | ———— | ———— | ———— | ———— | ———— | 1.1%2 ranked |
| Shareholder yield (Higher is better) | 2.9%FY2025 · SEC3rd of 858th47th | 2.6%FY2025 · SEC4th of 855th43rd | 1.7%FY2025 · SEC7th of 843rd30th | 0.2%FY2025 · SEC8th of 818th10th | 2.5%FY2025 · SEC5th of 852nd40th | 1.8%FY2025 · SEC6th of 845th31st | 4.8%FY2025 · SEC1st of 876th67th | 2.9%FY2025 · SEC2nd of 860th47th | 2.5%8 ranked |
| Dividend payout (Better neither way: ranked highest first) | 35.6%FY2025 · SEC1st of 265th48th | 27.5%FY2025 · SEC2nd of 251st35th | ———— | ———— | ———— | ———— | ———— | ———— | 31.5%2 ranked |
| Dividend per share (Better neither way: ranked highest first) | —— | $2.88FY2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | $2.88— |
| Years of dividend raises (Higher is better) | 15to 2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | —— | 15— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Quest Diagnostics Incorporated: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Labcorp Holdings Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; DexCom, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Guardant Health, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Mettler-Toledo International Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Illumina, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Medpace Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; IDEXX Laboratories, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Quest Diagnostics Incorporated | 14.1%FY2025 | 81st percentile in Healthcaremedian -7.7%, 674 companies | 77th percentile in USAmedian 3.5%, 2,595 companies |
| Labcorp Holdings Inc. | 9.9%FY2025 | 73rd percentile in Healthcaremedian -7.7%, 674 companies | 68th percentile in USAmedian 3.5%, 2,595 companies |
| DexCom, Inc. | 19.6%FY2025 | 88th percentile in Healthcaremedian -7.7%, 674 companies | 85th percentile in USAmedian 3.5%, 2,595 companies |
| Guardant Health, Inc. | -44.5%FY2025 | 33rd percentile in Healthcaremedian -7.7%, 674 companies | 16th percentile in USAmedian 3.5%, 2,595 companies |
| Mettler-Toledo International Inc. | — | — | — |
| Illumina, Inc. | 18.6%FY2025 | 87th percentile in Healthcaremedian -7.7%, 674 companies | 84th percentile in USAmedian 3.5%, 2,595 companies |
| Medpace Holdings, Inc. | 21.1%FY2025 | 89th percentile in Healthcaremedian -7.7%, 674 companies | 87th percentile in USAmedian 3.5%, 2,595 companies |
| IDEXX Laboratories, Inc. | 31.6%FY2025 | 95th percentile in Healthcaremedian -7.7%, 674 companies | 94th percentile in USAmedian 3.5%, 2,595 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Quest Diagnostics Incorporated | Labcorp Holdings Inc. | DexCom, Inc. | Guardant Health, Inc. | Mettler-Toledo International Inc. | Illumina, Inc. | Medpace Holdings, Inc. | IDEXX Laboratories, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $11.0 BSEC2nd | $14.0 BSEC1st | $4.7 BSEC3rd | $982 MSEC8th | $4.0 BSEC6th | $4.3 BSEC4th | $2.5 BSEC7th | $4.3 BSEC5th |
| 2024 | $9.9 BSEC2nd | $13.0 BSEC1st | $4.0 BSEC4th | $739 MSEC8th | $3.9 BSEC6th | $4.4 BSEC3rd | $2.1 BSEC7th | $3.9 BSEC5th |
| 2023 | $9.3 BSEC2nd | $12.2 BSEC1st | $3.6 BSEC6th | $564 MSEC8th | $3.8 BSEC4th | $4.5 BSEC3rd | $1.9 BSEC7th | $3.7 BSEC5th |
| 2022 | $9.9 BSEC2nd | $11.9 BSEC1st | $2.9 BSEC6th | $450 MSEC8th | $3.9 BSEC4th | $4.6 BSEC3rd | $1.5 BSEC7th | $3.4 BSEC5th |
| 2021 | $10.8 BSEC2nd | $13.1 BSEC1st | $2.4 BSEC6th | $374 MSEC8th | $3.7 BSEC4th | $4.5 BSEC3rd | $1.1 BSEC7th | $3.2 BSEC5th |
| 2020 | $9.4 BSEC2nd | $14.0 BSEC1st | $1.9 BSEC6th | $287 MSEC8th | $3.1 BSEC4th | $3.2 BSEC3rd | $926 MSEC7th | $2.7 BSEC5th |
| 2019 | $7.7 BSEC2nd | $11.6 BSEC1st | $1.5 BSEC6th | $214 MSEC8th | $3.0 BSEC4th | $3.5 BSEC3rd | $861 MSEC7th | $2.4 BSEC5th |
| 2018 | $7.5 BSEC2nd | $11.3 BSEC1st | $1.0 BSEC6th | $91 MSEC8th | $2.9 BSEC4th | $3.3 BSEC3rd | $705 MSEC7th | $2.2 BSEC5th |
| 2017 | $7.4 BSEC2nd | $10.3 BSEC1st | $719 MSEC6th | $50 MSEC8th | $2.7 BSEC4th | $2.8 BSEC3rd | $436 MSEC7th | $2.0 BSEC5th |
| 2016 | $7.2 BSEC2nd | $9.6 BSEC1st | $573 MSEC6th | $25 MSEC8th | $2.5 BSEC3rd | $2.4 BSEC4th | $422 MSEC7th | $1.8 BSEC5th |
| 2015 | $7.5 BSEC2nd | $8.7 BSEC1st | $402 MSEC6th | — | $2.4 BSEC3rd | $2.2 BSEC4th | $359 MSEC7th | $1.6 BSEC5th |
| 2014 | $7.4 BSEC1st | $6.0 BSEC2nd | $259 MSEC6th | — | $2.5 BSEC3rd | $1.9 BSEC4th | — | $1.5 BSEC5th |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Quest Diagnostics Incorporated#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Labcorp Holdings Inc.LH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $26.3 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $26.3 B (Oct 22, 2026) · revenue $14.0 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- DexCom, Inc.DXCM · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $29.9 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $29.9 B (Oct 22, 2026) · revenue $4.7 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Guardant Health, Inc.GH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $24.1 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $24.1 B (Oct 28, 2026) · revenue $982 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Mettler-Toledo International Inc.MTD · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $32.5 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $32.5 B (Oct 21, 2026) · revenue $4.0 B (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Illumina, Inc.ILMN · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $40.7 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $40.7 B (Oct 26, 2026) · revenue $4.3 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Medpace Holdings, Inc.MEDP · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $19.0 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19.0 B (Oct 30, 2026) · revenue $2.5 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- IDEXX Laboratories, Inc.IDXX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $41.5 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $41.5 B (Oct 6, 2026) · revenue $4.3 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Revvity, Inc.RVTY · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17.6 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $17.6 B (Oct 23, 2026) · revenue $2.9 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- IQVIA Holdings Inc.IQV · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $45.1 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $45.1 B (Oct 27, 2026) · revenue $16.3 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Waters CorporationWAT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $44.8 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $44.8 B (Oct 27, 2026) · revenue $3.2 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Charles River Laboratories International, Inc.CRL · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17.2 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $17.2 B (Oct 28, 2026) · revenue $4.0 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Agilent Technologies, Inc.A · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $48.8 B market cap against $27.8 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $48.8 B (Oct 19, 2026) · revenue $6.9 B (year to October 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.